Is Inovio (Ino) stock set to rebound?
Inovio started last year on a tear as it joined the hunt for a coronavirus vaccine. First, the company hit a major regulatory setback in September 2020. Is Inovio Stock Set to Rebound? Inovio Pharmaceuticals (NASDAQ: INO) has been one of the disappointments of the coronavirus vaccine race.
Why did Inovio Pharmaceuticals stock sink 6% Monday?
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were sinking 6.6% as of 3:47 p.m. EST on Monday. The decline came after analysts gave mixed reviews to the biotech's phase 1 data from COVID-19 vaccine candidate INO-4800.
What has Inovio been working on?
In the meantime, Inovio has been working on other, less headline grabbing candidates in its pipeline. On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le
Will Inovio’s VGX-3100 be another winning year for stocks?
On Tuesday, Inovio provided an update from the development of the Phase 3 program for VGX-3100, indicated to treat HPV-associated cervical high-grade squamous intraepithelial le In a little over two weeks, the curtain will close on what should go down as another winning year for the stock market.
Why Inovio stock dropped?
[Updated: Dec 17, 2021] INO Stock Decline This can be attributed to the spread of the new Covid-19 variant - Omicron. Inovio is developing INO-4800 - its Covid-19 vaccine candidate, which is now in late stage clinical trials and it is still several months before it can hit the market, subject to regulatory approval.
Will INO stock go back up?
Based on our forecasts, a long-term increase is expected, the "INO" stock price prognosis for 2027-06-11 is 3.660 USD. With a 5-year investment, the revenue is expected to be around +153.29%. Your current $100 investment may be up to $253.29 in 2027.
Is INO a good stock to Invest In?
21, INO stock has a Composite Rating of 19 out of a best-possible 99. The Composite Rating is a 1-99 measure of a stock's key fundamental and technical growth measures. This means Inovio stock outranks 19% of all stocks in terms of that metric. In 2020, the biotech lost $1.07 per share on $7.4 million in sales.
Is Inovio a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Whats happening with Inovio?
Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell.
What is the future of INO stock?
Stock Price Forecast The 4 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 8.00 and a low estimate of 1.00. The median estimate represents a +39.66% increase from the last price of 1.79.
Does inovio have a Covid vaccine?
In contrast, the heterologous booster market offers greater opportunities due to the endemic phase of COVID-19. So, instead of assessing INO-4800 as a two-dose vaccine, Inovio and its developmental partner Advaccine will examine the drug candidate as a heterologous booster to an inactivated COVID-19 vaccine.
Is inovio publicly traded?
Yes, Inovio Pharmaceuticals Inc is a publicly traded company.
The biotech just lost funding for the late-stage study of its COVID-19 vaccine candidate
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were crashing 27.4% as of 10:17 a.m. EDT on Friday. The big decline came after the company announced that the U.S. Department of Defense is discontinuing funding of the phase 3 study evaluating its COVID-19 vaccine candidate INO-4800.
Now what
The loss of funding for the phase 3 study of INO-4800 presents a huge setback for Inovio, so today's major sell-off of the biotech stock after this news isn't surprising.
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
The Defense Department will still fund the ongoing phase 2 study of INO-4800. Inovio now plans to conduct its late-stage study of the vaccine primarily outside the U.S. It also is evaluating another candidate, INO-4802, that targets coronavirus variants.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
An analyst downgrade caused gravity to kick in for the high-flying biotech stock
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were crashing 23.5% lower as of 3:18 p.m. EDT on Friday after plunging as much as 30.5% earlier in the day. The biotech reported its fourth-quarter results after the market closed on Thursday, topping Wall Street consensus revenue estimates but posting a wider-than-expected loss.
Now what
Inovio's fourth-quarter results really don't matter very much at this point, except for the company's cash position. Thanks to a big boost from stock sales through its at-the-market (ATM) facility, Inovio should have plenty of cash to fund operations at least into 2021.
Investors still appear to have doubts about two of the biotech's lead candidates
Inovio plans to initiate a phase 1 clinical study evaluating INO-4800 in immunizing against the novel coronavirus that causes COVID-19. The company will also present preliminary results from a couple of phase 2 studies for VGX-3100 in treating vulvar high-grade squamous intraepithelial lesions (HSIL) and anal HSIL this month.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were tanking by 10.3% as of 11:08 a.m. EST on Tuesday. The decline came after the company provided its fourth-quarter update following the market close on Monday.
Now what
Inovio's market cap of over $2 billion is based on expectations of strong growth. Anything that puts those expectations in doubt will cause the stock to fall.
Lingering disappointment over results announced on Tuesday and an FDA update are weighing on the stock
Those doubts could evaporate in the future. Or they could prove to be well-founded. It all depends on what happens next.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) were crashing 14.6% lower as of 10:55 a.m. EDT on Wednesday after falling as much as 20.7% earlier in the day. The drop stemmed from two factors.
Now what
Inovio's valuation is based entirely on investors' expectations for the company's pipeline. Any hint of bad news is going to cause the biotech stock to sink. And both factors behind Inovio's decline today are hints of bad news to some.
The biotech company continues to give up the gains it earned earlier this year
The primary thing for investors to watch now with Inovio is the biotech's pipeline progress. Inovio hopes to advance INO-4800 to a phase 2/3 clinical study after reviewing its phase 1 results with the FDA. The U.S. government's Operation Warp Speed is also funding a preclinical trial that includes INO-4800.
What happened?
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
So what
Shares of Inovio Pharmaceuticals ( NASDAQ:INO) closed Wednesday's trading session down by 6.8% after dropping by as much as 12.3% earlier in the day, despite the company not reporting any news. However, the biotech stock has been in sell-off mode for the past month (or so), and today is likely a continuation of that trend.
Now what
Inovio's stock went on a tear during the first half of the year -- gaining as much as 860% -- mostly thanks to its efforts to develop a vaccine for COVID-19. But the company's stock plunged after it released interim data from its phase 1 clinical trial for its coronavirus vaccine candidate, INO-4800, on Jun. 30.
